{"ok":true,"entity":{"id":"ucb","name":"UCB S.A.","entityType":"company","officialName":"UCB S.A.","canonicalName":"UCB S.A.","displayName":"UCB S.A.","category":"ベルギーのバイオ医薬品企業（神経・免疫領域）","shortDescription":"UCB S.A.はベルギーのブリュッセルに本社を置くグローバルなバイオ医薬品企業で、神経疾患と自己免疫疾患の領域の医薬品を、約40か国で展開しています。Euronext Brusselsにシンボル「UCB」で上場しており、2026年7月30日発表の2026年上期は売上収益42.7億ユーロ、BIMZELXの純売上は15.28億ユーロでした（2026年7月時点）。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.ucb.com/","updatedAt":"2026-10-20T07:33:40.757Z","secondaryClusters":[],"alias":["UCB","ユーシービー"],"searchKeywords":["UCB","ユーシービー","ベルギー製薬","BIMZELX","ビンゼレックス","ビメキズマブ","神経疾患","自己免疫疾患","Euronext Brussels"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}